October 06 2022 - 08:31AM
Business Wire
Alert
Share On Facebook
Leverages HeartBeam AIMIGo™ Platform to Address the Multibillion-Dollar Global Market for Detection of Atrial Arrhythmias
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. The product pipeline advancement allows for the addition of arrhythmia detection capabilities to address the multibillion-dollar global market for atrial fibrillation and other arrhythmia monitoring.
Building on HeartBeam’s recently issued patents, the broader product portfolio enables the following:
Introducing a 3-lead 3D vector electrocardiogram (VECG) credit card-sized device, the HeartBeam AIMIGo™ 3L, that records the X,Y,Z cardiac activity and displays the signals for clinician review, providing the regulatory foundation for subsequent products in HeartBeam’s product portfolio. The 510(K) submission to the United States Food and Drug Administration (FDA) is planned for Q4 2022.
Leveraging recently issued patents to incorporate both synthesized baseline and symptomatic 12-lead signals for enhanced diagnostic accuracy as well as the addition of atrial fibrillation detection capability in the AIMIGo 12L device for FDA 510(K) submission in Q2 2023.
Broadening of the product portfolio profile to enable smartwatch connectivity to HeartBeam’s platform in future products as an optional monitoring solution for the clinician and the patient.
“Adding smartwatch connectivity to our platform is a significant development as it extends our portfolio by enabling 24/7 heart monitoring capability,” said Branislav Vajdic, PhD, HeartBeam Founder and CEO. “Coupled with our breakthrough AIMIGo solution, we believe the overall HeartBeam system will bring a new and much higher level of diagnostic capability to cardiac patients. We continue to make steady progress in realizing our vision of bringing comprehensive cardiac care to patients anytime, anywhere.”
To overcome potential supply chain issues, procurement of critical components for the Company’s planned AIMIGo device production quantities for 2023 are in progress.
“We are pleased to announce that our novel AIMIGo heart attack solution will be significantly enhanced by the addition of automated atrial fibrillation detection and smartwatch connectivity,” said Jon Hunt, PhD, HeartBeam Chief Business Officer. “This is an immense step forward for our powerful AIMIGo platform as it adds a significant and established market for detection of atrial arrhythmias.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and
Recent BEAT News
- HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time • Business Wire • 04/25/2024 12:31:00 PM
- HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias • Business Wire • 04/09/2024 12:31:00 PM
- HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/20/2024 08:05:00 PM
- First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG • Business Wire • 03/14/2024 12:31:00 PM
- HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology • Business Wire • 03/07/2024 01:31:00 PM
- HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time • Business Wire • 03/05/2024 01:31:00 PM
- HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights • Business Wire • 12/14/2023 01:31:00 PM
- HeartBeam Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:01:00 PM
- HeartBeam Announces Expansion of Its Scientific Advisory Board • Business Wire • 11/09/2023 01:31:00 PM
- HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias • Business Wire • 11/07/2023 01:31:00 PM
- HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time • Business Wire • 10/31/2023 12:31:00 PM
- Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer • PR Newswire (US) • 09/27/2023 12:05:00 PM
- HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team • Business Wire • 09/26/2023 12:31:00 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- HeartBeam Reports Second Quarter 2023 Financial Results • Business Wire • 08/10/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:00:36 PM
- HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks • Business Wire • 08/09/2023 12:31:00 PM
- HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs • Business Wire • 08/08/2023 12:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2023 01:43:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2023 01:41:10 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 10:39:25 PM
- HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time • Business Wire • 07/27/2023 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2023 12:35:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM